Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Corcept Therapeutics  (Stock symbol: CORT )

149 Commonwealth Drive
Menlo Park, CA 94025
Website Company Summary Management Team

President/COO/Operations: Robert L. Roe (10/31/2001)
General Management: Susan Rinne (4/30/2012)
Finance: Anne M. LeDoux (03/28/2007) ; Gary C. Robb (8/22/2011)
General Counsel/Legal: Jim Fox

Outside board: (May no longer be on the board) David L. Mahoney (McKesson Former co-CEO) James N. Wilson (Corcept Therapeutics Chairman) Patrick G. Enright (Longitude Capital Managing Director) Daniel M. Bradbury (Amylin Pharmaceuticals Former CEO) Joseph L. Turner (Centaur Pharmaceuticals Former CFO) Leonard Baker (Sutter Hill Ventures) Joseph C. Cook (Amylin Pharmaceuticals Former CEO)
Advisory board: Florian Holsboer (Max Planck Institute of Psychiatry Executive Director);  Ned H. Kalin (University of Wisconsin Medical School Professor);  Edo Ronald de Kloet (Netherlands Organization for Scientific Research, NOW Chairman);  K. Ranga R. Krishnan (Duke University Medical Center in Durham, North Carolina Professor);  Bruce S. McEwen (Harold & Margaret Milliken Hatch Lab of Neuroendocrinology);  Charles B. Nemeroff (Emory University School of Medicine Professor);  Alan Schatzberg (Stanford University Department of Psychiatry and Behavioral)
Former outside board: Edward E. Penhoet (Alta Partners Director) Allen Andersson (Paperboy Ventures Chairman) James Harper (Eli Lilly Former CMO) Steve Kapp (Maverick Capital);  Alix Marduel (Alta Partners Managing Director)

Business description: Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States each year and for which there are no FDA - approved treatments. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. In August 2006 we announced negative top line results of one of our three Phase 3 studies. We expect to report the results the second study in September and the third in late 2006 or early 2007. Our program has been granted "fast track" status by the FDA. We have also initiated a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine.
Partners include: Eli Lilly ;  Xceleron

Rounds: 2
Recent Fundings: Nov 2002
Capital raised: 90.0M
Last Round: 11.6M
Ownership: Public  
Stock Symbol: CORT
VCs include: Alta PartnersSutter Hill VenturesThomas Weisel Venture PartnersSightLine PartnersCIBC World Markets;  Maverick Capital Equity Partners;  Paperboy Ventures;  Longitude Capital

Last Tweets


Last Mentions

Record updated: Feb 2019
Sector: Biotech
Year Founded: 1998
Headcount: 151-200 as of Jan 2019
Rounds: 2
Recent Fundings: Nov 2002
Capital Raised: 90.0M
Last Round: 11.6M
Ownership: Public  
Stock Symbol: CORT